Multiple sclerosis trials in Czechia

In Czechia 22 Also abroad 506

22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Brno, Brno-Stred, Choceň, Hradec Králové, Olomouc, Teplice
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Brno, Choceň, Hradec Králové, Jihlava 1, Olomouc, Ostrava, Prague, Zlin
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
Phase 2Taking people
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
Where
Brno-Stred, Hradec Králové, Pardubice, Prague 2, Prague 4, Teplice, Zlin
Age
18 years and over
People
100 worldwide
Run by
Celgene Corp.
See details and how to join2024-517745-14-00 · EU 2024-517745-14-00
No phaseTaking people
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
Where
Pardubice
Age
18 years and over
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07827586
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Brno-Stred, Jihlava 1, Novy Hradec Kralove, Pardubice, Zlin
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Where
Brno, Hradec Králové, Pardubice, Prague, Teplice, Zlín
Age
18 years to 70 years
People
200 worldwide
Run by
Celgene
See details and how to joinNCT06782490
Phase 3Taking people
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Where
Brno, Brno-Stred, Hradec Králové, Jihlava 1, Pardubice, Prague
Age
40 years to 70 years
People
400 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00
Phase 2Taking people
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
Where
Novy Hradec Kralove, Teplice
Age
18 years to 64 years
People
230 worldwide
Run by
Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00
Phase 3Taking people
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Where
Brno-Stred, Hradec Kralove, Jihlava 1, Novy Hradec Kralove, Teplice
Age
18 years to 64 years
People
125 worldwide
Run by
Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Brno, Hradec Králové, Jihlava, Prague, Teplice
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Where
Brno, Brno-Stred, Hradec Králové, Jihlava 1, Ostrava, Pardubice, Prague, Prague 2, Teplice, Zlin
Age
18 years to 60 years
People
160 worldwide
Run by
Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00
No phaseTaking people
Early Detection of Selected Neuropathologies in Motor Vehicle Drivers
Where
Olomouc
Age
18 years to 85 years
People
200
Run by
University Hospital Olomouc
See details and how to joinNCT07360886
Phase 2Taking people
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
Where
Brno-Stred, Jihlava 1, Prague 2
Age
18 years to 64 years
People
93 worldwide
Run by
Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Brno-Stred, Hradec Králové, Jihlava 1, Prague, Teplice
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00
No phaseNot yet taking people in Czechia
Comprehensive Rehabilitation Programme in People With Multiple Sclerosis: The RECONNECT-MS Study
Where
Prague
Age
18 years to 65 years
People
45
Run by
Charles University, Czech Republic
See details and how to joinNCT07666958
Phase 1Not yet taking people in Czechia
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
Where
Hradec Králové, Jihlava 1, Olomouc, Teplice, Zlin
Age
18 years to 65 years
People
222 worldwide
Run by
Polpharma Biologics International AG
See details and how to joinNCT07606521 · EU 2026-525314-61-00
Phase 2Taking people
Psilocybin Therapy for Psychological Distress in Palliative Patients
Where
Klecany
Age
18 years and over
People
108 worldwide
Run by
University Medical Center Groningen
See details and how to joinNCT06782724 · EU 2023-510488-36-01
No phaseTaking people
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
Where
Prague
Age
18 years and over
People
7,000 worldwide
Run by
icometrix
See details and how to joinNCT06280755
No phaseEnrolling by invitation
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
Where
Prague
Age
18 years and over
People
750 worldwide
Run by
icometrix
See details and how to joinNCT07032246
No phaseNot yet taking people in Czechia
Comprehensive Therapeutic Program For People With Multiple Sclerosis
Where
Prague
Age
Up to 75 years
People
26
Run by
Charles University, Czech Republic
See details and how to joinNCT07248657
Phase 4Taking people
The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
Where
Ostrava
Age
18 years and over
People
100
Run by
Fakultni Nemocnice Ostrava
See details and how to join2024-514549-12-00 · EU 2024-514549-12-00
No phaseTaking people
The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related to QoL in MS Patients
Where
Ostrava
Age
18 years and over
People
40
Run by
University Hospital Ostrava
See details and how to joinNCT06218927